People in their thirties will be offered an alternative to the Oxford / AstraZeneca vaccine, UK government officials confirmed on Friday, saying a reduction in the rate of Kovid-19 infection could mean the potential risks of the disease outweigh the risks of the disease.
On Friday morning the Joint Committee on Immunization and Vaccination announced that their advice for those under 40 years of age had been changed where alternative-vaccines were available.
Analysis by the UK regulator found that AstraZeneca vaccine recipients for the population as a whole had almost rare and sometimes severe blood clotting conditions, but it had become one in about 60,000 people in their 30s.
Similarly, the condition resulted in the deaths of approximately 2 out of every 1 million people receiving the AstraZeneca vaccine in a large population, with 4.5 million people dying between the ages of 30 and 39.
The change in the guide is not expected to affect the pace of the UK vaccination campaign, and according to public health officials, all adults are still being offered the first vaccination at least by the end of July.
JCIVO concludes that there are no safety concerns regarding the second dose of the AstraZeneca vaccine – if someone has already been given their first dose, they should also be given a second.
The UK government data released on Thursday found that among the British, at least the first dose of the AstraZeneca vaccine was found, a total of 242 cases of rare blood clots that were 33 more than a week earlier. Of these 242 cases, 49 died.
Two-thirds of people affected by this condition are under 60 years of age.
A few weeks after the move Full discussion This is another blow to the Oxford University and the Anglo-Swedish pharmaceutical company inside JCVI in proposing a change of direction, which was designed to create a low-cost vaccine for the world but has suffered multiple setbacks.
The JCVI suggested that all healthy people under the age of 30 be vaccinated if available, after which the GCVI suggested that the UK suddenly changed the tax on AstraZeneca Jab, the mainstay of its inoculation program, last month.
Denmark has banned it altogether and several European countries have restricted it to the elderly because of evidence over the past few weeks that rare blood clots are more common in young people.
A study by the Winton Center for Risk and Evidence Communication at Cambridge University, published in March, found that only those under the age of 30 had a comparable risk of Covid-19 and AstraZeneca JB depending on the rate of infection in the community at any given time.
However, the success of one of the most effective UK vaccination programs in the world has changed the calculus of risk benefits. Young people are now much less at risk from the virus than ever before.
Robert Dingwall, a professor of sociology at Nottingham Trent University and a member of the JCVI, said: “All the data is much stronger in the right direction than expected.
“The declining rate of infection has reduced the risk of any delay in vaccination,” added Dingwall, who said he had not participated in any JCVI discussions on direct policy on AstraZeneca Jab because he was advising the agency on the vaccine dilemma. .
Melania Savili, director of vaccine research and development at the Coalition for Epidemic Preparedness Innovations, which finances and coordinates the development of vaccines, said the calculation of risk benefits was influenced by the amount of virus infection in a particular country.
“In the UK, we are in a much less risky position at the moment,” he added. “This is an issue that countries need to look at on an ongoing basis: an advantage-risk profile for these very rare events.”
The latest data from the Office for National Statistics, released last week, shows that virus infections are declining rapidly across the UK. An estimated 54,200 people in England tested positive for Covid-19 in the last week of April 24, down from about 1 in 1,010 and down from 1 in 480 two weeks ago.
The University of Oxford says it is up to the relevant national body to decide how best to vaccinate its national population. AstraZeneca did not immediately respond to a request for comment.